Skip to main content

Turn Cancer Immunotherapy Effective in Most Patients

Project description

Restoring immune system response in cancer patients

Recent advances in cancer immunotherapy after introduction of immune checkpoint inhibitors demonstrated great potential by achieving previously impossible 5-year survival rates for patients with metastatic cancers. However, a great number of patients worldwide remain unresponsive to immunotherapy and often do not have any other therapeutic options. French biotech start-up Stimunity aims to address this problem through the development of new drugs that activate the stimulator of interferon genes pathway to restore the innate immune system of these unresponsive patients and induce a potent and durable antitumour immune response. The company strategy is based on a safe virus-like particle technology that allows to encapsulate the best-known natural activators and efficiently deliver them into immune cells. The EU-funded STI-001 project will allow Stimunity to confirm the feasibility of the technological approach, assess regulatory issues, and validate the marketing and business plans.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

STIMUNITY SAS
Net EU contribution
€ 50 000,00
Address
Rue D'amsterdam 57
75008 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 21 429,00